Contact a rep button
contact a rep

stay connected!

Fill in the required fields to stay up to date with news and announcements about VPRIV.
*Required Field

One or more required fields are invalid.

Please review and submit this form again.

thank you!

You have been successfully signed up to receive
communications from Takeda

Click here to unsubscribe

Hero section background Female patient

VPRIV CLINICAL PROGRAM OVERVIEW

VPRIV’s safety and efficacy profile was evaluated in the largest clinical trial program of an ERT for type 1 Gaucher disease1–3

VPRIV was evaluated in 99 patients across three clinical trials, which included pediatric (aged ≥4 years), adult, and geriatric (aged ≥65 years) patients.1 Some of these patients were then enrolled into one phase III, open-label, long-term extension trial conducted in adult and pediatric patients (n=93).1,4

*Treatment-naïve: patients who had not received disease-specific treatment within the 30 months prior to starting VPRIV5,6,8
Treatment-experienced: patients previously treated with imiglucerase for a minimum of 30 consecutive months prior to switching to VPRIV7,9

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS

Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.

Initiate VPRIV in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment.